Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Clinical Experience With JAK Inhibitor in AD
Ruth Ann Vleugels, MD, MPD, MBA, and Christopher Bunick, MD, PhD, provide their clinical experience with Janus Kinase (JAK) inhibitors and the importance of patient compliance with these agents.
EP: 1.JAK Inhibitor Overview and Relevance to AD
EP: 2.Comparing Current Treatment Agents for AD
Now Viewing
EP: 3.Clinical Experience With JAK Inhibitor in AD
EP: 4.Experts Present Background on Long-Term Safety Study of Upadacitinib for AD
EP: 5.Experts on Results of Long-Term Safety Study of Upadacitinib for AD
EP: 6.Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD
EP: 7.Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents
EP: 8.Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study
EP: 9.Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study
EP: 10.Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline
EP: 11.Box Warning and JAK Inhibitor
EP: 12.JAK Inhibitor Selectivity
EP: 13.Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study
EP: 14.Evolving the Standard of Care for AD: Safety and Treatment Response
EP: 15.Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor
EP: 16.AD Endotypes and Outcomes
EP: 17.Final Thoughts on JAK Inhibitor for AD
Related Videos
Related Content
